The preventive effects of hyperoside on lung cancer in vitro by inducing apoptosis and inhibiting proliferation through Caspase 3 and P53 signaling pathway.
Though advanced surgical operation and chemotherapy have been under taken, lung cancer remains one of the most aggressive and fatal human malignancies with a low survival rate. Thus, novel therapeutic strategies for prevention and remedy are urgently needed in lung cancer. Hyperoside, known as quercetin 3 O b d galactopyranoside, is a natural flavonol glycoside discovered in plants of genera Hypericum, displaying anti oxidant, anticancer, and anti inflammatory properties. In the study, we attempted to investigate whether hyperoside could inhibit lung cancer progression via Caspase 3 and P53 regulated cell death. In in vitro and in vivo experiments, we explored hyperoside at three different dosages on cell apoptosis, cell proliferation, cell migration, cell invasion, cell cycle distribution, the related signalling pathways, as well as xenograft tumor growth. Our data suggested that hyperoside exerted inhibitory role in lung cancer development. Inhibition of NF kB transcriptional activity, Caspase 9/Caspase 3 activation, the cell cycle arrest, and suppression of cell proliferation related signaling pathway led to the lung cancer inhibition. Further, via mice xenograft model in vivo, we indicated that hyperoside completely impeded tumor growth through angiogenesis inhibition. Our study illustrated that hyperoside might provide a synergistic anticancer effects that warrant further study and investigation due to its potential role in clinical applications.
Biomedicine pharmacotherapy Biomedecine pharmacotherapie